Connect with us

Health

Single dose of 'magic mushrooms' provides 5 years of depression relief, researchers find

Published

on

Single dose of 'magic mushrooms' provides 5 years of depression relief, researchers find

NEWYou can now listen to Fox News articles!

Psilocybin, the main psychoactive ingredient in magic mushrooms, could alleviate depression for at least five years after just one dose, according to a new study.

The research, presented June 18 at the Psychedelic Science 2025 conference in Denver, followed up with patients who had been diagnosed with clinical depression — also known as major depressive disorder (MDD) — and had participated in a previous psilocybin treatment study in 2020.

“Most people who participated in our trial reported improvements in depression symptom intensity or in the ways in which they experienced depression in their life, lasting up to five years after the trial,” study co-author Alan Davis, director of the Center for Psychedelic Drug Research and Education at The Ohio State University, told Fox News Digital.

PSYCHEDELICS AS POTENTIAL MENTAL HEALTH TREATMENT ARE EXPLORED BY TRUMP ADMINISTRATION

Advertisement

Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin in Toronto, Ontario, told Fox News Digital that the outcome speaks to the “exciting” potential of psilocybin and other psychedelic-based treatments in treating MDD and other mental health conditions.

“The results of the study are certainly very encouraging,” said Drysdale, who was not involved in the study.

A worker holds dried psychedelic mushrooms. The results of the new study are “certainly very encouraging,” said one pharmaceutical company executive.  (James MacDonald/Bloomberg via Getty Images)

Earlier studies pointed toward the possibility of psilocybin as a potential antidepressant, prompting researchers to conduct the first-ever randomized clinical trial.

The initial 2020 trial, published in JAMA Psychiatry, included 24 patients with major depressive disorder. Half received psilocybin at the beginning of the trial, and the other half received the treatment eight weeks later. 

Advertisement

Each patient also underwent 11 hours of psychotherapy.

WHAT IS KETAMINE THERAPY? MORMON REALITY STARS TOUT CONTROVERSIAL TREATMENT

One month after treatment, 17 patients reported experiencing symptom relief. Fourteen of those reported full remission from depression, according to the published study.

“The effectiveness of psilocybin therapy after a single or only a few administrations represents another substantial advantage over commonly used antidepressants that require daily administration,” the researchers wrote.

Patients appeared to respond much faster to psychedelics than to traditional antidepressants, the researchers stated. (James MacDonald/Bloomberg via Getty Images)

Advertisement

The new study aimed to explore the longer-term effects of this treatment on 21 of the original trial participants.

Sixty-seven percent reported being in remission from depression five years after treatment, and they also had less anxiety and easier daily functioning.

“The study doesn’t account for naturalistic changes that could have affected their depression in the five years since the main trial.”

For those whose depression came back, many still reported lasting benefits in their attitudes, perspectives and ability to pursue things that were meaningful to them, Davis told Fox News Digital.

“Certainly, more controlled and rigorous study is required, but at least anecdotally, these findings are very interesting, and I am cautiously optimistic about the potential for extended efficacy provided by these types of treatments,” Drysdale added.

Advertisement

Sixty-seven percent of participants reported being in remission from depression five years after treatment, and they also had less anxiety and easier daily functioning. (JASON CONNOLLY/AFP via Getty Images)

Other factors may have also played a role in the participants’ long-term mental health benefits, such as psychotherapy sessions or other antidepressants, experts agreed.

“The study doesn’t account for naturalistic changes that could have affected their depression in the five years since the main trial, and the sample is not representative of the population of people suffering with depression,” Davis told Fox News Digital.

PARKINSON’S PATIENTS WHO TAKE ‘MAGIC MUSHROOMS’ SEE KEY BENEFITS, STUDY FINDS

Psilocybin has also been explored as a potential treatment for post-partum depression (PPD), which affects as many as one in seven new mothers.

Advertisement

A 2022 study outlined the potential role of psychedelics in PPD cases, finding that psilocybin has been shown to catalyze a sense of “reconnection” in new mothers.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“This effect in PPD, by fostering a sense of ‘reconnection’ for the mother, may allow for improved mood and maternal sensitivity toward the infant, which can positively impact maternal role gratification and the mother-infant relationship,” the researchers stated.

In February, Cleveland Clinic reported on an upcoming study that explores single-dosing psilocybin as a way to treat PPD.

Psilocybin has been explored as a potential treatment for post-partum depression (PPD), which affects as many as one in seven new mothers. (iStock)

Advertisement

The trial, now in its second phase, focuses on RE104, a proprietary drug similar to psilocybin. 

Study participants will undergo multiple physical and mental health tests.

Potential risks and limitations

Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, has emphasized the importance of administering psychedelics in a safe setting when treating mental health conditions.

For more Health articles, visit www.foxnews.com/health

“Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia,” Moss previously told Fox News Digital. 

Advertisement

Experts recommend that therapeutic use of psychedelics should be carefully managed by medical experts.

“Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials.”

To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. 

Other factors may have also played a role in the participants’ long-term mental health benefits, noted an expert (not pictured), such as psychotherapy sessions or other antidepressants. (iStock)

Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News’ senior medical analyst, previously interviewed two of the country’s top researchers on psychedelics: Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone.

Advertisement

“They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses,” Siegel told Fox News Digital at the time.

“Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts,” Siegel added.

Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed reporting.

Advertisement

Health

Male fertility rates crash as doctors reveal health threats: ‘Something very wrong’

Published

on

Male fertility rates crash as doctors reveal health threats: ‘Something very wrong’

NEWYou can now listen to Fox News articles!

Scientists and physicians agree that there’s been a general decline in male fertility — but they aren’t sure why.

Social media buzz has pointed to a few environmental exposures as potential factors, including cellphones and electric vehicles.

But the reality is “more complicated” than that, according to experts who recently spoke to National Geographic.

ORIGIN OF DEADLY CANCER AFFECTING YOUNG ADULTS REVEALED IN ALARMING REPORT

Advertisement

Although it’s not clear whether the decline is at a stage where it should be considered a crisis, numbers show that overall fertility — demographically measured by the number of babies born compared to women of child-bearing age — has decreased.

Scientists and physicians agree that there’s been a general decline in male fertility. (iStock)

Dr. Alex Robles of the Columbia University Fertility Center in New York confirmed that clinical practitioners are “certainly seeing more couples where the male factor contributes to infertility.”

CELLPHONE HEALTH RISKS IN FOCUS OF NEW GOVERNMENT STUDY: ‘VERY CONCERNED’

“At least one-third of couples we evaluate have some male component,” he told Fox News Digital.

Advertisement

A 2017 meta-analysis published in Oxford Journals: Human Reproduction Update found that sperm counts in Western countries have declined by almost 60% globally since 1973. The 2023 update confirmed these same results.

Urologists can track declining fertility in sperm quality, while demographic data uses the number of babies born compared to women of child-bearing age as a benchmark, according to National Geographic. (iStock)

Lead study author and epidemiologist Hagai Levine warned that this trend could lead to human extinction if it isn’t addressed.

“This is the canary in the coal mine,” Levine, public health physician at the Hebrew University-Hadassah Braun School of Public Health, told National Geographic. “It signifies that something is very wrong with our current environment, as lower sperm counts predict morbidity and mortality.”   

DOCTORS WARN SOME POPULAR FOODS AND DRINKS COULD BE SECRETLY SABOTAGING MEN’S TESTOSTERONE LEVELS

Advertisement

These findings have been contradicted by other studies, however. A 2025 Cleveland Clinic analysis of studies from the last 53 years found sperm counts to be steady.

“There is no evidence to suggest that this decline is the cause of a precipitous decline in the ability to cause pregnancies,” primary study author Scott Lundy, a reproductive urologist at Cleveland Clinic, told National Geographic. “Most men, even with a modest decline in sperm counts, will still have no issues conceiving.”

Potential factors of decline

Multiple lifestyle factors can lead to a decline in male fertility, Robles noted, including obesity, smoking and diet, as well as environmental exposures and delayed parenthood.

National Geographic also reported that heavy drinking and marijuana use directly contribute to declining fertility and that quitting these habits, while also exercising and losing weight, can help.

Smoking of any kind can contribute to a decline in fertility, according to experts. (iStock)

Advertisement

Systemic inflammation, infection and disease can also have a “big, profound effect on the current status of fertility,” Lundy told National Geographic. 

Those who are getting over a fever from an infection, like the flu or COVID, will have a “drastically lower” sperm count for three months, he said.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Male infertility can also be a marker of overall health, according to Robles. “Poor semen parameters are associated with other medical conditions and may signal underlying metabolic, hormonal or environmental issues,” he told Fox News Digital.

Experts recommend seeing a doctor to discuss fertility concerns instead of relying on the internet. (iStock)

Advertisement

Allan Pacey, deputy dean of the Faculty of Biology, Medicine and Health at the University of Manchester, told National Geographic that the decline could be caused by increased use of contraception, as well as men waiting longer to have children or choosing not to have them at all.

CLICK HERE FOR MORE HEALTH STORIES

Microplastics have also been raised on social media as a potential culprit, but the effects are unclear, according to experts.

There is some evidence of endocrine-disrupting chemicals — which are substances found in reusable plastics and some disposable products — altering male fertility, Lundy revealed to National Geographic.

Myths busted

Concerns have circulated on social media that keeping a cellphone in a front pocket could harm male fertility. While Lundy said such an effect is biologically possible, there is currently no scientific evidence supporting the claim.

Advertisement

Another common myth is that infertility is mostly a women’s issue, Robles noted, but male factors contribute to about one-third to one-half of all cases.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The claim that taking supplements can boost sperm counts is another common myth, he said, adding that it’s not backed by strong scientific evidence.

“Men should focus on factors that we know matter: maintaining a healthy weight, avoiding tobacco, limiting alcohol and managing chronic health conditions,” Robles advised. 

One common myth is that infertility is mostly a women’s issue, but male factors contribute to about one-third to one-half of all cases. (iStock)

Advertisement

Experts recommend seeing a urologist to address fertility concerns. Robles said his approach begins with an evaluation, semen analysis, hormonal testing and medical history, while also exploring lifestyle factors.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

In addition to traditional treatment options, Robles said his fertility center also uses advanced tools that incorporate AI and robotics.

“Technologies like this are expanding options for patients who previously had very limited paths to biological parenthood,” he said.

Advertisement
Continue Reading

Health

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier

Published

on

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier


Advertisement





How To Curb Late-Night Cravings and Make Weight Loss Easier | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

Published

on

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

NEWYou can now listen to Fox News articles!

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge.

Advertisement

That’s according to new research from the University of California San Diego, which found that a specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk.

The researchers analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study in the late 1990s, according to the study’s press release. 

KEY FITNESS MEASURE IS STRONG PREDICTOR OF LONGEVITY AFTER CERTAIN AGE, STUDY FINDS

The women ranged from 65 to 79 years of age and showed no signs of cognitive decline at the start of the study.

After tracking the participants for up to 25 years, the researchers concluded that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with future mild cognitive impairment and dementia. 

Advertisement

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge. (iStock)

Women who had higher levels of p-tau217 at the beginning of the study were “much more likely” to develop the disease. The findings were published today in JAMA Network Open.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” first author Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine, told Fox News Digital. 

“These biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia.”

“Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin,” he added.

Advertisement

This long lead time could open the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life, according to Shadyab.

A specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk. (iStock)

“As the research advances, these biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia,” he said.

This risk relationship wasn’t the same across the board, however. Women over 70 with higher p-tau217 levels had “poorer cognitive outcomes” compared to those under 70, as did those with the APOE ε4 gene, which is a known risk factor for Alzheimer’s disease.

Advertisement

The study also found that p-tau217 was a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy compared to those who received a placebo.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” said senior author Linda K. McEvoy, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, in the release. 

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” a researcher said. (iStock)

“This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Advertisement

Blood tests for Alzheimer’s disease are still being studied and are not recommended for routine screening in people without symptoms, Shadyab noted. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

More research is needed before this approach can be considered for clinical use prior to cognitive symptoms. 

Future studies should investigate how other factors — like genetics, hormone therapy and age-related medical conditions — might interact with plasma p-tau217, the researchers added.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

“The study examined only older women, so the findings may not necessarily apply to men or younger populations,” Shadyab noted. “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”

Continue Reading
Advertisement

Trending